Framingham, Mass., August 3, 2007-- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today that its financial results for the second quarter 2007 will be released on Thursday, August 9, 2007 before the Nasdaq market opens. Geoffrey F. Cox, Ph.D., Chairman of the Board, Chief Executive Officer and President, will lead the call on August 9 starting at 10:00 a.m. Eastern Time. You may access the live internet broadcast or the subsequent archived recording, on GTC's website at http://www.gtc-bio.com or as follows:
Live Call - In the United States, dial 1-800-573-4752
Outside the United States, dial 617-224-4324
Reference call ID: when prompted 79553667
Audio Archive - In the United States, dial 888-286-8010
Outside the United States, dial 617-801-6888
Reference call ID: when prompted 60285577
NOTE: a replay of the call will be available one hour following the end of the call and will be accessible until August 16, 2007. The earnings webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.earnings.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
About GTC Biotherapeutics
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. In August 2006, ATrynŽ, GTC's recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. This was the first approval anywhere in the world of a therapeutic protein produced from a transgenic animal. We have developed goats that have the human antithrombin gene linked to a milk-protein promoting gene so that they express this protein in their milk. This transgenic approach provides the opportunity to produce recombinant forms of proteins, such as antithrombin, that are difficult to express in economically viable quantities in conventional production systems.
ATrynŽ is in a Phase III clinical study in preparation for requesting market approval from the U.S. Food and Drug Administration. LEO Pharma A/S, ATrynŽ's partner in Europe, Canada and the Middle East, has launched the product for the approved indication in Europe and is initiating a Phase II dose ranging study in treating disseminated intravascular coagulation associated with severe sepsis, a market estimated to be $2 to 3 billion in the U.S. In addition, GTC has established a strategic collaboration with LFB Biotechnologies of France to jointly develop recombinant forms of human plasma proteins and monoclonal antibodies. The first program of the collaboration will be to develop recombinant human factor VIIa as a potential treatment for hemophilia in patients with antibodies to other coagulation factors.
CONTACT:
GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications
(508) 370-5374 or tom.newberry@gtc-bio.com Feinstein Kean Healthcare for GTC
Francesca DeVellis
(617) 577-8110 or francesca.devellis@fkhealth.com
Copyright 2007 GTC Biotherapeutics, All Rights Reserved